RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal disease resulting from deficiency in the α-L-iduronidase (IDUA) hydrolase and subsequent accumulation of glycosaminoglycan (GAG). Clinically, enzyme replacement therapy (ERT) with IDUA achieves negligible neurological benefits presumably due to blood-brain-barrier (BBB) limitations. To investigate the plant lectin ricin B chain (RTB) as a novel carrier for enzyme delivery to the brain, an IDUA:RTB fusion protein (IDUAL), produced in N. benthamiana leaves, was tested in a murine model of Hurler syndrome (MPS I). Affect mice (n=3 for each group) were intravenously injected with a single dose of IDUAL (0.58, 2 or 5.8mgIDUAequivalents/kg) and analyzed after 24h. IDUA activities in liver, kidney and spleen increased significantly, and liver GAG levels were significantly reduced in all three groups. Plasma IDUA levels for all treated groups were high at 1h after injection and decreased by 95% at 4h, indicating efficient distribution into tissues. For long-term evaluations, IDUAL (0.58 or 2mg/kg, 8 weekly injections) was intravenously injected into MPS I mice (n=12 for each group). Thirteen days after the 8th injection, significant IDUA activity was detected in the liver and spleen. GAG levels in tissues including the brain cortex and cerebellum were significantly reduced in treated animals. Treated MPS I mice also showed significant improvement in neurocognitive testing. ELISA results showed that while there was a significant antibody response against IDUAL and plant-derived IDUA, there was no significant antibody response to RTB. No major toxicity or adverse events were observed. Together, these results showed that infusion of IDUAL allowed for significant IDUA levels and GAG reduction in the brain and subsequent neurological benefits. This RTB-mediated delivery may have significant implications for therapeutic protein delivery impacting a broad spectrum of lysosomal, and potentially neurological diseases.

• Authors: Li Ou, Michael J Przybilla, Brenda Koniar, Chester B Whitley
• Journal: Molecular genetics and metabolism (Mol Genet Metab) Vol. 123 Issue 2 Pg. 105-111 (02 2018) ISSN: 1096-7206 [Electronic] United States
• PMID: 29198892 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Drug Carriers
• Plant Lectins
• Iduronidase

Topics

• Animals
• Central Nervous System Diseases (enzymology, therapy)
• Disease Models, Animal
• Drug Carriers (chemistry)
• Drug Delivery Systems
• Enzyme Replacement Therapy
• Female
• Humans
• Iduronidase (administration & dosage, physiology)
• Lysosomes (enzymology)
• Male
• Mice
• Mice, Inbred C57BL
• Mice, Knockout
• Mucopolysaccharidosis I (enzymology, therapy)
• Plant Lectins (administration & dosage, chemistry)
• Tobacco (chemistry)